Predictive Values of Blood-Based RNA Signatures for the Gemcitabine Response in Advanced Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is expected to be the second cause of cancer death by 2022. For nearly 80% of patients, diagnosis occurs at an advanced, nonsurgical stage, making such patients incurable. Gemcitabine is still an important component in PDAC treatment and is most often used as...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-10-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/11/3204 |
| _version_ | 1797549250115010560 |
|---|---|
| author | David Piquemal Florian Noguier Fabien Pierrat Roman Bruno Jerome Cros |
| author_facet | David Piquemal Florian Noguier Fabien Pierrat Roman Bruno Jerome Cros |
| author_sort | David Piquemal |
| collection | DOAJ |
| description | Pancreatic ductal adenocarcinoma (PDAC) is expected to be the second cause of cancer death by 2022. For nearly 80% of patients, diagnosis occurs at an advanced, nonsurgical stage, making such patients incurable. Gemcitabine is still an important component in PDAC treatment and is most often used as a backbone to test new targeted therapies and there is, to date, no routine biomarker to predict its efficacy. Samples from a phase III randomized trial were used to develop through a large approach based on blood-based liquid biopsy, transcriptome profiling, and machine learning, a nine gene predictive signature for gemcitabine sensitivity. Patients with a positive test (41.6%) had a significantly longer progression free survival (PFS) (3.8 months vs. 1.9 months <i>p</i> = 0.03) and a longer overall survival (OS) (14.5 months vs. 5.1, <i>p</i> < 0.0001). In multivariate analyses, this signature was independently associated with PFS (HR = 0.5 (0.28–0.9) <i>p</i> = 0.025) and OS (HR = 0.39 (0.21–0.7) <i>p</i> = 0.002). |
| first_indexed | 2024-03-10T15:11:57Z |
| format | Article |
| id | doaj.art-66be200ce8794568b19034c24e0914aa |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T15:11:57Z |
| publishDate | 2020-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-66be200ce8794568b19034c24e0914aa2023-11-20T19:15:57ZengMDPI AGCancers2072-66942020-10-011211320410.3390/cancers12113204Predictive Values of Blood-Based RNA Signatures for the Gemcitabine Response in Advanced Pancreatic CancerDavid Piquemal0Florian Noguier1Fabien Pierrat2Roman Bruno3Jerome Cros4Acobiom, 1682 Rue de la Valsière, 34790 Grabels, FranceAcobiom, 1682 Rue de la Valsière, 34790 Grabels, FranceAcobiom, 1682 Rue de la Valsière, 34790 Grabels, FranceAcobiom, 1682 Rue de la Valsière, 34790 Grabels, FranceDepartment of Pathology, Beaujon Hospital-Université de Paris–INSERM U1149, 92110 Clichy, FrancePancreatic ductal adenocarcinoma (PDAC) is expected to be the second cause of cancer death by 2022. For nearly 80% of patients, diagnosis occurs at an advanced, nonsurgical stage, making such patients incurable. Gemcitabine is still an important component in PDAC treatment and is most often used as a backbone to test new targeted therapies and there is, to date, no routine biomarker to predict its efficacy. Samples from a phase III randomized trial were used to develop through a large approach based on blood-based liquid biopsy, transcriptome profiling, and machine learning, a nine gene predictive signature for gemcitabine sensitivity. Patients with a positive test (41.6%) had a significantly longer progression free survival (PFS) (3.8 months vs. 1.9 months <i>p</i> = 0.03) and a longer overall survival (OS) (14.5 months vs. 5.1, <i>p</i> < 0.0001). In multivariate analyses, this signature was independently associated with PFS (HR = 0.5 (0.28–0.9) <i>p</i> = 0.025) and OS (HR = 0.39 (0.21–0.7) <i>p</i> = 0.002).https://www.mdpi.com/2072-6694/12/11/3204pancreatic cancerpredictive diagnosisliquid biopsygemcitabine |
| spellingShingle | David Piquemal Florian Noguier Fabien Pierrat Roman Bruno Jerome Cros Predictive Values of Blood-Based RNA Signatures for the Gemcitabine Response in Advanced Pancreatic Cancer Cancers pancreatic cancer predictive diagnosis liquid biopsy gemcitabine |
| title | Predictive Values of Blood-Based RNA Signatures for the Gemcitabine Response in Advanced Pancreatic Cancer |
| title_full | Predictive Values of Blood-Based RNA Signatures for the Gemcitabine Response in Advanced Pancreatic Cancer |
| title_fullStr | Predictive Values of Blood-Based RNA Signatures for the Gemcitabine Response in Advanced Pancreatic Cancer |
| title_full_unstemmed | Predictive Values of Blood-Based RNA Signatures for the Gemcitabine Response in Advanced Pancreatic Cancer |
| title_short | Predictive Values of Blood-Based RNA Signatures for the Gemcitabine Response in Advanced Pancreatic Cancer |
| title_sort | predictive values of blood based rna signatures for the gemcitabine response in advanced pancreatic cancer |
| topic | pancreatic cancer predictive diagnosis liquid biopsy gemcitabine |
| url | https://www.mdpi.com/2072-6694/12/11/3204 |
| work_keys_str_mv | AT davidpiquemal predictivevaluesofbloodbasedrnasignaturesforthegemcitabineresponseinadvancedpancreaticcancer AT floriannoguier predictivevaluesofbloodbasedrnasignaturesforthegemcitabineresponseinadvancedpancreaticcancer AT fabienpierrat predictivevaluesofbloodbasedrnasignaturesforthegemcitabineresponseinadvancedpancreaticcancer AT romanbruno predictivevaluesofbloodbasedrnasignaturesforthegemcitabineresponseinadvancedpancreaticcancer AT jeromecros predictivevaluesofbloodbasedrnasignaturesforthegemcitabineresponseinadvancedpancreaticcancer |